Clinical Use of AMD3100 to Mobilize CD34+ Cells in Patients Affected by Non-Hodgkin's Lymphoma or Multiple Myeloma

We agree with Grignani et al that given the relative importance of the CXCR4/SDF-1 axis in tumor cell migration, further studies evaluating the potential mobilization of cancer cells in patients with multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) following AMD3100 are warranted.Although this issue was not addressed in our phase I study published in the March 15, 2004, issue of the Journal of Clinical Oncology, 1 two studies have since evaluated tumor cell mobilization in patients with MM and NHL.The University of Arkansas group administered a combination of AMD3100 at 240 g/kg per